Abstract
The hepatitis B vaccine recently licensed for use in the United States has undergone several field trials in high-risk populations and has proven to be immunogenic, efficient and safe. The hepatitis vaccine is unique in that the hepatitis B virus (HBV), the ultimate source of the vaccine, cannot be grown in tissue culture. The immunizing antigen, purified from plasma of healthy human carriers of HBV, consists of noninfectious 22 nm particles of hepatitis B surface antigen (HBsAg), produced as excess viral surface protein and released in the bloodstream. Although the HBsAg particles are highly purified and inactivated, there is some concern that the vaccine may contain traces of host material or infective adventitious agents, which may trigger undesirable effects in the recipients. Ideally, a hepatitis B vaccine candidate should have the following properties: 1) be free of normal human serum protein contaminants, 2) be free of potential residual infectious HBV, 3) be free of other viruses and nucleic acid, 4) have a high degree of immunogenicity when administered in conjunction with an adjuvant suitable for use in humans, 5) be independent of human HBV carriers as a source of immunogenic material, 6) have a reproducible composition, 7) cost less than the present vaccine, and 8) be available in unlimited supplies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Dreesman, G. R., Hollinger, F. B., McCombs, R. M., and Melnick, J. L. (1972). Infec. Immun. 5:213.
Cabrai, G. A., Marciano-Cabral, F., Funk, G. A., Sanchez, Y., Hollinger, F. B., Melnick, J. L., and Dreesman, G. R. (1978). J. Gen. Virol. 38:339.
Sanchez, Y., Ionescu-Matiu, I., Hollinger, F. B., Melnick, J. L., and Dreesman, G. R. (1980). J. Gen. Virol. 48:273.
Dreesman, G. R., Hollinger, F. B., Sanchez, Y., Oefinger, P., and Melnick, J. L. (1981). Infec. Immun. 32:62.
Dreesman, G. R., Hollinger, F. B., McCombs, R. M., and Melnick, J. L. (1973). J. Gen. Virol. 19:129.
Tiollais, P., Charnay, P., and Vyas, G. N. (1981). Science 213:406.
Sanchez, Y., Ionescu-Matiu, I., Melnick, J. L., and Dreesman, G. R. (1983). J. Med. Virol. 11:115.
Simons, K., Helenius, A., Leonard, K., Sarvas, M., and Gething, M. J. (1978). Proc. Natl. Acad. Sci. USA 75:5306.
Zuckerman, A. J., Howard, C. R., and Skelly, J. (1981). in Hepatitis B Vaccine, P. Maupas and P. Guesry, eds., Elsevier/North-Holland Biomedical Press, Amsterdam, p. 251.
Ionescu-Matiu, I., Sanchez, Y., Fields, H. A., and Dreesman, G. R. (1983). J. Virol. Methods 6:41.
Charnay, P., Pourcel, C., Louise, A., Fritsch, A., and Tiollais, P. (1979). Proc. Natl. Acad. Sci. USA 76:2222.
Valenzuela, P., Gray, P., Quiroga, M., Zaldivar, J., Goodman, A. M., and Rutter, W. J. (1979). Nature 280:815.
Pasek, M., Gotto, T., Gilbert, W., Zink, B., Schaller, H., MacKay, P., Leadbetter, G., and Murray, K. (1979). Nature 282:575.
Peterson, D. L. (1981). J. Biochem. 256:6975.
Bull, H. B. and Bresse, K. (1975). Arch. Biochem. Biophys. 161:665.
Chou, P. Y. and Fasman, G. D. (1978). Adv. Enzym. 47:45.
Lerner, R. A., Green, N., Alexander, H., Liu, F.-T., Sutcliffe, J. G., and Shinnick, T. M. (1981). Proc. Natl. Acad. Sci. USA 78:3403.
Bhatnagar, P. K., Papas, E., Blum, H. E., Milich, D. R., Nitecki, D., Karels, M. J., and Vyas, G. N. (1982). Proc. Natl. Acad. Sci. USA 79:4400.
Prince, A. M., Ikram, H., and Hopp, T. P. (1982). Proc. Natl. Acad. Sci. USA 79:579.
Dreesman, G. R., Sanchez, Y., Ionescu-Matiu, I., Sparrow, J. T., Six, H. R., Peterson, D. L., Hollinger, F. B., and Melnick, J. L. (1982). Nature 295:158.
Sanchez, Y., Ionescu-Matiu, I., Sparrow, J. T., Melnick, J. L., and Dreesman, G. R. (1982). Intervirology 18:209.
Kennedy, R. C., Ionescu-Matiu, I., Adler-Storthz, K., Henkel, R. D., Sanchez, Y., and Dreesman, G. R. (1983). Intervirology 19:176.
Ionescu-Matiu, I., Kennedy, R. C., Sparrow, J. T., Culwell, A. R., Sanchez, Y., Melnick, J. L., and Dreesman, G. R. (1983). J. Immunol. 130:1947.
Peterson, D. L. (1982). in Viral Hepatitis, 1981 International Symposium, W. Szmuness, H. J. Alter and J. E. Maynard, eds., Franklin Institute Press, Philadelphia, p. 707.
Kennedy, R. C. and Dreesman, G. R. (1983). J. Immunol. 130:385.
Kennedy, R. C., Sanchez, Y., Ionescu-Matiu, I., Melnick, J. L., and Dreesman, G. R. (1982). Virology 122:219.
Kennedy, R. C., Dreesman, G. R., Sparrow, J. T., Culwell, A. R., Sanchez, Y., Ionescu-Matiu, I., Hollinger, F. B., and Melnick, J. L. (1983). J. Virol. 46:653.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Springer Science+Business Media New York
About this chapter
Cite this chapter
Dreesman, G.R., Ionescu-Matiu, I., Sanchez, Y., Kennedy, R.C., Sparrow, J.T., Melnick, J.L. (1984). Hepatitis B Surface Antigen Polypeptide and Synthetic Peptide Vaccines. In: Millman, I., Eisenstein, T.K., Blumberg, B.S. (eds) Hepatitis B. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0369-3_17
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0369-3_17
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-0371-6
Online ISBN: 978-1-4899-0369-3
eBook Packages: Springer Book Archive